Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Clinical trial NCT03172910 · COMPLETED
Trial details
- NCT number
- NCT03172910
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-08
- Primary completion
- 2019-11-12
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.